🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating globally, with data suggesting more than 82 million infections annually. Notably increased rates are seen in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the context of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Medical experts are particularly alarmed about the surge in drug-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program found that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Therapies Secure Clearance

One new antibiotic, alternatively called a brand name, was cleared by the US FDA in December for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, created by the drugmaker GSK, also received approval in concurrent days. This medication, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a major breakthrough in the management of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Research Study Results and Global Access

As per findings released by a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which combines two antibiotics. The trial enrolled hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the rights to make available and distribute the drug in a wide range of developing nations.

Medical professionals treating patients have expressed positive views. Access to a easy-to-administer therapy such as this is described as a "revolutionary step" for gonorrhoea control. This is considered vital to reduce the burden of the disease for people and to stop the proliferation of untreatable gonorrhoea around the world.